Field Of Vision
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2014; 20(28): 9217-9228
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9217
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?
Antonella Scalera, Giovanni Tarantino
Antonella Scalera, Giovanni Tarantino, Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, 80131 Naples, Italy
Giovanni Tarantino, National Cancer Institute “Pascale Foundation”-IRCS, 83013 Mercogliano (Av), Italy
Author contributions: Tarantino G conceived the research; Scalera A analyzed the studies and drafted the manuscript; Tarantino G critically revised the literature.
Correspondence to: Giovanni Tarantino, MD, Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Via Sergio Pansini 5, 80131 Naples, Italy. tarantin@unina.it
Telephone: +39-81-7462024 Fax: +39-81-5466152
Received: December 20, 2013
Revised: April 1, 2014
Accepted: April 15, 2014
Published online: July 28, 2014
Abstract

It was estimated that from 2002 to 2008 the risk of developing cancer increased a quarter-fold in men and two-fold in women due to excessive BMI. Obesity, metabolic syndrome and type 2 diabetes mellitus are strictly related and are key pathogenetic factors of non-alcoholic fatty liver disease (NAFLD), the most frequent liver disease worldwide. The most important consequence of the “metabolic epidemics” is the probable rise in the incidence of hepatocarcinoma (HCC), and NAFLD is the major causative factor. Adipose tissue is not merely a storage organ where lipids are preserved as an energy source. It is an active organ with important endocrine, paracrine, and autocrine actions in addition to immune functions. Adipocytes produce a wide range of hormones, cytokines, and growth factors that can act locally in the adipose tissue microenvironment and systemically. In this article, the main roles of insulin growth factor (IGF)-1 and IGF-2 are discussed. The role of IGF-2 is not only confined to HCC, but it may also act in early hepato-carcinogenesis, as pre-neoplastic lesions express IGF-2 mRNA. IGF-1 and IGF-2 interact with specific receptors (IGF-1R and IGF-2R). IGF-1R is over-expressed in in vitro and in animal models of HCC and it was demonstrated that IGF ligands exerted their effects on HCC cells through IGF-1R and that it was involved in the degeneration of pre-neoplastic lesions via an increase in their mitotic activity. Both IGF-2R and TGF β, a growth inhibitor, levels are reduced in human HCC compared with adjacent normal liver tissues. Another key mechanism involves peroxisome proliferator-activated receptor (PPAR)γ. In in vitro studies, PPARγ inhibited various carcinomas including HCC, most probably by regulating apoptosis via the p21, p53 and p27 pathways. Finally, as a clinical consequence, to improve survival, efforts to achieve a “healthier diet” should be promoted by physicians and politicians.

Keywords: Hepatocarcinoma, Non-alcoholic fatty liver disease, Insulin growth factor, Peroxisome proliferator-activated receptor γ, Adipokines

Core tip: Obesity, metabolic syndrome and type 2 diabetes mellitus are strictly related and are key pathogenetic factors in non-alcoholic fatty liver disease, one of the most frequent liver diseases worldwide. It is necessary to stress that one of the most important consequences of the “metabolic epidemics” is the probable rise in the incidence of cancers, particularly hepatocarcinoma. Thus, to improve survival, efforts to achieve a “healthier diet” should be promoted by physicians and politicians, even though no changes in genes have been observed in the postprandial state induced after the acute effect of specific diets in patients exhibiting non-alcoholic fatty liver disease and insulin resistance.